ALZHEIMER'S® ASSOCIATION

Business Consortium

Quarter 3 2025 Newsletter

Mission of AABC

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Theresa Devins (tdevins@cogrx.com) or Dr. Paul Slowey (pds@4saliva.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

Congratulations to the New AABC Co-Chair

Congratulations to Dr. Paul Slowey, who was elected as the new AABC co-chair for a two-year term. Dr. Slowey is the CEO at Oasis Diagnostics Corporation. We are delighted to have him serving in this role. The Alzheimer's Association extends its gratitude to outgoing co-chair Dr. Ornit Chiba-Falek for her service to AABC. Under her leadership, AABC has grown in membership and hosted events that have advanced our mission. We look forward to working with the two co-chairs, Dr. Devins and Dr. Slowey, in the upcoming year and would like to thank everyone for their continued participation.

Welcome New Members

AABC is growing! Welcome to:

- **Sharon Blaettler, W Vallen Graham, & Maniji Kazmi, Aggregate Biosciences**
  Aggregate Biosciences is pioneering a new approach to treating amyloid diseases by targeting what others miss: structural diversity. While most therapies treat all amyloid aggregates the same, the field is beginning to recognize that distinct "morphotypes" exist in patients and drive different aspects of disease. Conventional treatments overlook this, resulting in mixed efficacy and avoidable side effects. Aggregate Biosciences is the first company purpose-built to precisely target the toxic morphotypes that actually drive disease. Our proprietary platform identifies and isolates these harmful structures - enabling a new generation of safer, more effective therapies. We are launching with a first-in-class antibody for Alzheimer's, powered by a scalable platform that supports precision therapies and diagnostics across the entire spectrum of amyloid diseases.
- **Lilly Lee & Ralph Kern, Cognito Therapeutics**
  Cognito Therapeutics is a late-stage clinical neurotechnology company developing disease-modifying therapies for neurodegenerative diseases. Its lead product, Spectris™, is a non-invasive, at-home neuromodulation device designed to restore gamma brain wave activity disrupted in Alzheimer's disease. At the 2025 AD/PD™ conference, Cognito presented new data from its OVERTURE trial showing that Spectris preserved structural brain integrity in patients with mild-to-moderate Alzheimer's. Over six months, patients using Spectris daily maintained corpus callosum volume (+0.58%) compared to a decline in matched ADNI controls (-0.91%), a significant net difference of +1.49% ($p<0.004$). Spectris also induced robust 40 Hz gamma oscillations that correlated with MRI measures of brain health, including temporal lobe volume and occipital cortical thickness. With no observed ARIA, >80% adherence, and FDA Breakthrough Device Designation, Spectris is now being evaluated in HOPE, a pivotal trial enrolling 670 patients. Cognito's platform represents a potentially safer, scalable, and transformative approach to treating Alzheimer's disease.

» **Sam Agus, Simona Piccirella, & Michael Rasche, Diadem SpA**
Diadem SpA was founded as a spin-out of the University of Brescia (Italy). The company is developing tools to optimize decision-making, when treating individuals with cognitive concerns, with a focus on Alzheimer's disease (AD). The availability of disease-modifying treatments, for individuals with early-symptomatic AD has highlighted the need, to detect AD symptoms, as early as possible. More importantly, the lack of biomarkers that can facilitate decision-making prior to onset of symptoms creates a significant bottleneck, adding burden and stress to patients, caregivers, and providers. The lead product is AlzoSure® Predict, a simple blood test, that is detecting the unfolded form of p53, which is specific to AD (U-p53AZ). This test is developed for the purpose of prognosis, i.e., to detect the risk of clinically significant deterioration, and provide the timeframe for it to occur, in individuals, who are cognitively unimpaired, and individuals with early-symptomatic AD. Based on analysis of nearly 1000 samples from the AIBL dataset, and from the ADRC site at WashU, AlzoSure® Predict has received a CE-IVD mark in EU, and is developed in the US, under a breakthrough device designation (BDD). Diadem SpA is also developing AlzoSure® Confirm, a blood-based diagnostic test, with the capability to provide a highly accurate differential diagnosis, as to the cause of cognitive decline,with promising results in early analysis. Diadem's founding lead investor is Milan-based Panakes Partners, a venture capital firm that finances promising high potential biomedical companies in Europe and Israel. Diadem SpA is preparing for commercialization of AlzoSure® Predict in collaboration with global strategic partners.

» **Brian Packard, Stephen L'Heureux & William Zamboni, HealthSpan Research LLC**
HealthSpan Research is pioneering an exosome-based therapeutic for Alzheimer's disease that targets neurovascular dysfunction and blood–brain barrier breakdown, which are key drivers of both disease initiation and progression. Our approach centers on the use of allogenic exosomes, whose effectiveness has been validated in well-established cellular models, leveraging a proprietary microRNA screening panel and a scalable, pharmaceutical-grade exosome manufacturing platform. Preclinical studies show these exosomes can restore endothelial integrity, enhance mitochondrial function, and reduce neuroinflammation—findings that align with and extend existing scientific knowledge. By integrating molecular screening, combinatorial therapeutic design, and scalable manufacturing, HealthSpan Research is advancing a rigorously validated exosome platform with the potential to deliver disease-modifying therapies across the continuum of Alzheimer's Disease. We are committed to collaborating and contributing to the collective mission of accelerating research and translating discoveries into impact—together with the Alzheimer's Association and the research community.

» **Hank Durschlag, Rob Davidson, Michael Kleiman, Dan Kelly, Hjarna Scientific**
Hjarna Scientific, led by Founder Hank Durschlag, CEO Rob Davidson, Chief Scientific Officer Michael Kleiman, and Chief Revenue Officer Dan Kelly, is proud to join the Alzheimer's Association Business Consortium and collaborate with leaders dedicated to fighting dementia. Our company is pioneering the use of conversational artificial intelligence to make early cognitive screening accessible and scalable. Hjarna's AI-powered platform proactively engages individuals through brief, automated phone calls, analyzing subtle patterns in speech to identify the earliest signs of cognitive impairment from the comfort of a person's own home. This innovative approach provides healthcare partners with critical insights to facilitate timely diagnosis and intervention, creating a new pathway for proactive cognitive care. We are committed to developing technology that meets people where they are and empowers a future where early detection is a reality for everyone. To learn more about our work, please visit us at hjarna.io and connect with our team on LinkedIn at https://www.linkedin.com/company/hjarna-scientific/.

» **Jeffrey Weiss, Micron Opthalmic**
Micron Ophthalmic is advancing the field of Alzheimer's diagnostics with its patented Dynamic Light-Scattering Spectroscopy (DLS) device, an optical technology that measures the movement of normal proteins within the retina. The test is noninvasive, quantitative, inexpensive (0.05 cents), and takes just 3 seconds to perform. Unlike the incumbent PET-amyloid imaging and biological matrix assays, which are costly, invasive, and time-consuming, DLS provides a rapid, quantitative readout of disease-related protein dysfunction at a tiny fraction of the cost. Clinical validation studies have demonstrated that DLS can identify Alzheimer's disease at least two years before standard diagnostic confirmation, with 100% sensitivity based on current data. Importantly, in cases where PET-amyloid imaging produced inconclusive findings, DLS showed predictive utility in signaling future Alzheimer's onset, highlighting its ability to provide earlier and more reliable insights into disease progression. The quantitative nature of the test allows for consistent tracking of biomarker changes over time, making it a powerful tool not only for early detection but also for monitoring therapeutic response in interventional trials. By reducing costs dramatically, compared to PET imaging, lumbar puncture, and even blood tests, and eliminating the need for invasive procedures, Micron Ophthalmic's solution improves accessibility for large patient populations, enhances the efficiency of trial recruitment and stratification, lowers those barriers which have typically stood between patient and diagnostic, and shifts the paradigm for clinical systems handling Alzheimer's detection.

» **Christopher Kan, Sampling Human**
Sampling Human is a life science tools company building AI-driven, end-to-end data pipelines to enable clinical-grade, single-cell genomic products. The company is introducing a novel platform for decoding single-cell information that makes highly precise insights in prenatal testing, oncology, and neurodegenerative medicine much faster, scalable and affordable. Headquartered in Berkeley, CA, Sampling Human collaborates with leading institutions worldwide to make single-cell resolution the new standard in healthcare.

AABC News

ADvantage Therapeutics

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04®, the company's phase 2 Alzheimer's candidate. The SBIR program is one of the most competitive NIH funding initiatives, designed to support small businesses advancing cutting-edge science with high commercial potential. More info can be found here.

bioExpert

2025 BMFZ Meeting Dusseldorf: The 6th Symposium on Neurodegenerative Diseases: Amyloids Prions, Clinical Trials and Biomarkers
Date: November 12-14, 2025
Venue: Haus der Universität in Duesseldorf, Germany
The registration and poster abstract submission is open now. Register today.

Alzheimer's disease and other neurodegenerative diseases represent one of the greatest challenges for health research today. The 2025 Düsseldorf Symposium on Neurodegenerative Diseases brings together leading experts from a wide range of disciplines and serves as a forum for interdisciplinary perspectives on the pathology of Alzheimer's and related diseases.

Further information on the 2025 BMFZ Meeting Dusseldorf: The 6th Symposium on Neurodegenerative Diseases can be found at: https://www.ipb.hhu.de/duesseldorf-juelich-symposium

The Program is finalized with world-renowned speakers, including Nobel Prize Winner Stanley Prusiner: https://www.ipb.hhu.de/duesseldorf-juelich-symposium/program

Further speakers will be selected from the abstract submissions.

We hope you will join us in North Rhine-Westphalia's beautiful capital for three days of lively discussions, innovative ideas, collaboration and networking!

The organizing committee (Inga Kadish, Carsten Korth, Alfons Schnitzler, Thomas van Groen, Sascha Weggen and Dieter Willbold)

Progenicyte Therapeutics, Inc

The latest development from Progenicyte Therapeutics, Inc is advancing an innovative diagnostic product: Retinal Amyloid Detection. In addition to our ongoing work on small-molecule therapeutics.

This technology aims to provide a non-invasive, accessible method for identifying amyloid deposits through the retina, serving as a potential early biomarker for Alzheimer's disease. By leveraging retinal imaging, we hope to enable earlier detection, support more accurate monitoring, and ultimately improve patient outcomes through timely intervention. For more information, please visit our website: Retinal Amyloid Detection.

Coupled with our small-molecule program designed to stimulate endogenous neural stem cells, Progenicyte's dual approach reflects our mission to tackle Alzheimer's disease from both therapeutic and diagnostic perspectives. We believe that combining novel treatments with precise, non-invasive detection methods will be critical in addressing this growing public health challenge.

Clarity Technologies

Clarity announced positive results from an early feasibility study evaluating **VR-based 40 Hz gamma sensory stimulation in 11 patients with Mild Cognitive Impairments (MCI) and early-stage Alzheimer's disease (AD). The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2025**, demonstrate that delivering synchronized light and sound stimulation via VR is safe, well-tolerated, and associated with acute memory improvements in this patient population. These results complement the positive results previously obtained from 16 cognitively healthy elderly individuals, which were published in Scientific Reports on 5 August. For more details, refer to this article.

Update on Alzheimer's data: https://www.clarity-technologies.com/feasibility-study-alzheimers-cohort

Scientific Reports publication (healthy elders): https://www.nature.com/articles/s41598-025-13725-6

AriBio

AriBio is a Phase 3 biotechnology company focused on developing innovative therapies for neurodegenerative diseases. The lead asset AR1001, a disease-modifying small molecule, is in a global Phase 3 Alzheimer's trial (AR1001-ADP3-US01, POLARIS-AD, NCT05531526) across the US, EU, UK, China, Korea, and Canada, with topline data expected in 2026. The company recently completed global enrollment with 1,535 patients, exceeding its target. As the largest sample source, AriBio supported strategic partner Fujirebio's FDA clearance of the first blood-based diagnostic test for Alzheimer's disease. This milestone advances early diagnosis—critical for timely intervention as we work towards disease-modifying therapy of AR1001 (AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer's Disease and Neurodegeneration).

AriBio has also broadened AR1001's global reach through two regional licensing agreements. First, Fosun Pharma licensed exclusive rights to AR1001 in the Greater China region, benefiting the largest aging population in the world (Fosun Pharma Sign Exclusive Licensing Agreement for AR1001 in China). Second, AriBio granted Arcera (Acino) exclusive rights to market AR1001 in selected countries in MENA, LATAM, and CIS regions ensuring treatment to patients in emerging markets with huge unmet needs: AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease.

Social Media

Follow our LinkedIn We look forward to using the page to foster partnerships and communications.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).